# Jaguar Health (JAGX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/JAGX
## Company Profile
- Ticker: JAGX
- Exchange: NASDAQ
- Sector: Pharmaceuticals
- Location: United States
- Tags: Biopharma
## Stock Data
- Close: 1.3 USD
- Market cap: 11220157.41 USD
- Last updated: 2026-07-17
## Business Overview
Jaguar Health is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
## Why The Stock Is Moving

JAGX is trading as a small specialty-pharma name where the market mainly watches product execution, pipeline expansion, and financing risk. The stock usually responds to partner updates, label progress, and commercial traction rather than the broader biotech tape.

## Geographic Base

Headquartered in the United States and listed on NASDAQ, Jaguar Health is followed within the biotech universe for its exposure to catalyst-driven execution.

## Business Model

Jaguar Health follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.

## Landscape Position

Compared with more mature healthcare peers, Jaguar Health sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.

## Future Catalysts

- Near-term catalysts are likely to come from commercialization commentary, rare-disease development updates, and any financing or partnership news that changes the capital profile.
- Investors also watch whether the company can keep expanding crofelemer-based opportunities into additional gastrointestinal indications.
- Because the company is small and focused, even modest changes in execution or access can have an outsized effect on sentiment.
- Conference participation and regulatory milestones can matter, but commercial follow-through and non-dilutive funding often matter more for the stock.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.